Thieno[2,3-c] and [3,2-c]pyridines, process for their preparation and therapeutic applications thereof

Therapeutic composition having bloodplatelet aggregation inhibiting properties, comprising an effective amount of a compound selected from the compounds having the formulae:

• ##STR6## in which:
• R.sup.1 is selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy and C.sub.1-6 alkylthio;
• R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, phenyl, carboxy, benzyloxycarbonyl and trimethoxybenzyloxycarbonyl;
• R.sup.3 is selected from hydrogen, C.sub.1-12 alkyl, phenyl, benzyl, benzyl substituted by one to three substituents selected from halogen, cyano, C.sub.1-6 alkoxy and carbomethoxy;
• and n is selected from 0 and 1;
• and their therapeutically acceptable acid addition salts, together with a pharmaceutically acceptable carrier.

Process for the preparation of a compound selected from the compounds having the formulae:

• ##STR7## in which:
• R.sup.1 is selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy and C.sub.1-6 alkylthio;
• R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, phenyl, carboxy, benzyloxycarbonyl and trimethoxybenzyloxycarbonyl;
• R.sup.3 is selected from hydrogen, C.sub.1-12 alkyl, phenyl, benzyl, benzyl substituted by one to three substituents selected from halogen, cyano, C.sub.1-6 alkoxy and carbomethoxy;
• and n is selected from 0 and 1, and the therapeutically acceptable acid addition salts of said compounds, comprising oxidizing a compound selected from the compounds having the formulae (III) and (IV), respectively:
• ##STR8## in which R.sup.1, R.sup.2, R.sup.3 and n have the above-defined meanings, at room temperature within a two-phase water-benzene system, in the presence of a quaternary ammonium salt as phase transfer catalyst.

Therapeutic composition having anti-thrombotic and anti-sludge properties, comprising an effective amount of a compound selected from the compounds having the formulae:

• ##STR9## in which:
• R.sup.1 is selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy and C.sub.1-6 alkylthio;
• R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, phenyl, carboxy, benzyloxycarbonyl and trimethoxybenzyloxycarbonyl;
• R.sup.3 is selected from hydrogen, C.sub.1-12 alkyl, phenyl, benzyl, benzyl substituted by one to three substituents selected from halogen, cyano, C.sub.1-6 alkoxy and carbomethoxy;
• and n is selected from 0 and 1;
• and their therapeutically acceptable acid addition salts, together with a pharmaceutically acceptable carrier.

Therapeutic composition having antalgic properties, comprising an effective amount of a compound selected from the compounds having the formulae:

• ##STR10## in which:
• R.sup.1 is selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy and C.sub.1-6 alkylthio;
• R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, phenyl, carboxy, benzyloxycarbonyl and trimethoxybenzyloxycarbonyl;
• R.sup.3 is selected from hydrogen, C.sub.1-12 alkyl, phenyl, benzyl, benzyl substituted by one to three substituents selected from halogen, cyano, C.sub.1-6 alkoxy and carbomethoxy;
• and n is selected from 0 to 1;
• and their therapeutically acceptable acid addition salts, together with a pharmaceutically acceptable carrier.

Therapeutic composition having anti-inflammatory properties, comprising an effective amount of a compound selected from the compounds having the formulae:

• ##STR11## in which:
• R.sup.1 is selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy and C.sub.1-6 alkylthio;
• R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, phenyl, carboxy, benzyloxycarbonyl and trimethoxybenzyloxycarbonyl;
• R.sup.3 is selected from hydrogen, C.sub.1-12 alkyl, phenyl, benzyl, benzyl substituted by one to three substituents selected from halogen, cyano, C.sub.1-6 alkoxy and carbomethoxy;
• and n is selected from 0 and 1;
• and their therapeutically acceptable acid addition salts, together with a pharmaceutically acceptable carrier.